Today: 2 February 2026
Subscribe
Browse Category

LSE:MPH News 30 December 2025

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

NEW YORK, December 29, 2025, 23:16 ET — Market closed Mereo BioPharma Group plc shares closed down 87.65% at $0.29 on Monday after the company disclosed late-stage data that failed to hit a key fracture-rate endpoint for setrusumab, its lead rare-disease program. The stock traded between $0.20 and $0.30, with about 241 million shares changing hands, according to the company’s…
30 December 2025
····

Stock Market Today

  • Exxon Mobil Q4 Beat Highlights Permian and Guyana Output, Valuation at Crossroads
    February 2, 2026, 1:48 PM EST. Exxon Mobil (XOM) posted better-than-expected Q4 2025 results, driven by record upstream production in the Permian Basin and Guyana, alongside notable cost savings. The stock gained 15.29% over the past month and delivered a 36.88% total return over the past year. Despite trading above the average analyst target price of $134.04 at $141.40, a valuation model from Helzur suggests the stock is 7.1% overvalued, with a fair value estimated at $132.00 per share. This assessment emphasizes Exxon's strong cash flow, disciplined capital allocation, and operational excellence without relying on high oil price assumptions. Risks remain from commodity price volatility and potential policy-driven decarbonization impacts on upstream and Low Carbon Solutions business units.
Go toTop